In recent years, with advances in technology, there have been tremendous progresses in defining the molecular landscape of AML, and novel AML entities were included in the most recent World Health Organization (WHO) classifications (4), including AML with NPM1 or CEBPA mutations. Here, CEBPA is linked to acute myeloid leukemia.